TAM
PRTK

Tiverton Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Tiverton Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,756
Closed -$30K – 670
2018
Q4 		$30K Buy
+5,756
New +$43.7K ﹤0.01% 475

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tiverton Asset Management's PRTK Position: Q1 2019 in Review

Tiverton Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2019, closing a stake of 5,756 shares — an estimated $30K sold.

Tiverton Asset Management first reported a position in PRTK in Q4 2018 and held it in 1 quarter. The position peaked at $30K in Q4 2018. 94 funds tracked by Wall St. Rank hold PRTK as of Q1 2019.

  • Tiverton Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 5,756 Paratek Pharmaceuticals, Inc. shares in Q1 2019, an estimated $30K.
  • Tiverton Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Tiverton Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $30K in Q4 2018.
  • 94 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2019.

Based on Tiverton Asset Management's 13F filing for Q1 2019, filed 13 May 2019.